| Objective To analyze the changes of bone mineral density (BMD) and bone metabolism index in female patients with Graves and after treatment of 131I, and to provide scientific clinical evidence for the treatment of bone metabolic disorder in patients with Graves’ disease. Methods Data of 90 female patients with Graves’ disease after 131I treatment in our hospital from May 2013 to May 2015 were retrospectively analyzed. According to their menopause status, the patients were divided into postmenopausal group and premenopausal group, with 45 cases in each group. BMD of the lumbar spine and hip in patients of two groups was measured before and after the treatment using dual energy X-ray absorptiometry. Serum calcium (CA), phosphorus (P), parathyroid hormone (PTH), alkaline phosphatase (ALP), and osteocalcin (BGP) were detected. Results Before the treatment, BMD in postmenopausal group was slightly lower, but the bone metabolism index were slightly higher than that in premenopausal group, with no significant statistical difference (P>0.05). After the treatment, the improvement in premenopausal group was more than the in postmenopausal group and before treatment. BMD of the hip and waist increased significantly. Levels of ALP and BGP decreased significantly, with statistical difference (P<0.05). The levels of serum Ca, P, and PTH were not significantly different between the two groups (P>0.05). Conclusion 131I therapy can improve BMD and bone metabolism in female patients with Graves’ disease and has a positive influence in prevention of osteoporosis. |